title: Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis.
abstract: IGF-I is an anabolic hormone which has been reported to increase bone formation in several conditions of undernutrition. Advanced liver cirrhosis is associated with osteopenia and also with low serum levels of IGF-I. Previous results showed that low doses of IGF-I increase osteoblastic activity and decrease bone reabsorption in early liver cirrhosis. The aim of this study was to evaluate whether IGF-I-treatment also induces beneficial effect on osteopenia associated with advanced cirrhosis. Rats with ascitic cirrhosis were divided into two groups: group CI (n=10) which received saline and group CI+IGF (n=10) which were treated with IGF-I (2 microg/100 g bw x day, sc, during 21 days). Healthy controls which received saline were studied in parallel (CO n=10). On the 22nd day, the animals were sacrificed, and bone parameters were analyzed in femur. Posterior-anterior diameter was similar in all groups. No significant differences were observed in bone content of calcium, total proteins, collagen and hydroxyapatite in cirrhotic rats as compared with controls. However, CI rats showed significant reductions in total bone density (-13.5%, p<0.001) assessed by densitometry and radiological study. In CI+IGF rat bone density (assessed by densitometry) improved significantly as compared with CI animals. In summary, osteopenia characterized by loss of bone mass and preserved bone composition was found in rats with advanced cirrhosis induced by CCl4 and phenobarbital in drinking water. This bone disorder is partially restored by treatment with low doses of IGF-I during only three weeks. Thus, IGF-I could be considered as a possible therapy for osteopenia associated with advanced liver cirrhosis.
authors.affiliation: Department of Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Cemborain
authors.forename: I
authors.initials: I
authors.lastname: Castilla-Cortázar
authors.forename: M
authors.initials: M
authors.lastname: García
authors.forename: B
authors.initials: B
authors.lastname: Muguerza
authors.forename: G
authors.initials: G
authors.lastname: Delgado
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Sánchez
authors.forename: A
authors.initials: A
authors.lastname: Picardi
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology*; D002251:Carbon Tetrachloride / Q000633:toxicity; D003720:Densitometry; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000150:complications*; D008297:Male; D010634:Phenobarbital / Q000633:toxicity; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
chemical_list: D007334:Insulin-Like Growth Factor I; D002251:Carbon Tetrachloride; D010634:Phenobarbital